Cargando…
The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis
BACKGROUND: Choosing Wisely is a high-profile campaign seeking to reduce the use of low-value care. We investigated the impact of a Choosing Wisely Canada recommendation against using a combination of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for the man...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
CMA Impact Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828945/ https://www.ncbi.nlm.nih.gov/pubmed/36735223 http://dx.doi.org/10.9778/cmajo.20210185 |
_version_ | 1784867373769031680 |
---|---|
author | Laba, Tracey-Lea Worthington, Heather C. Cheng, Lucy Chan, Fiona K.I. Bansback, Nick Law, Michael R. |
author_facet | Laba, Tracey-Lea Worthington, Heather C. Cheng, Lucy Chan, Fiona K.I. Bansback, Nick Law, Michael R. |
author_sort | Laba, Tracey-Lea |
collection | PubMed |
description | BACKGROUND: Choosing Wisely is a high-profile campaign seeking to reduce the use of low-value care. We investigated the impact of a Choosing Wisely Canada recommendation against using a combination of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for the management of hypertension, heart failure or diabetic nephropathy on population-level use of these medications in British Columbia, Canada. METHODS: We identified all people (any age) who were continuously registered with BC’s Medical Service Plan between 2010 and 2017 with the targeted conditions. Using prescription claims data and an interrupted time-series analysis, we estimated the number of people on combination therapy per month, the proportion of days covered (PDC) by combination therapy per month and proportion of all combination prescriptions started per month in the 2 years before and after the introduction of the recommendation on Oct. 29, 2014. RESULTS: Of 1 104 593 people (mean age 65 yr, standard deviation 16 yr) in our study cohort, 4.6% were exposed to combination therapy, largely prescribed by family physicians (84%). The number of people on combination therapy and the PDC were declining before the recommendation, but the proportion of combination prescriptions started in the 2 years before the recommendation was increasing. After the recommendation, we observed no statistically significant changes in any outcome. The pre-existing downward trend of the monthly number of people decelerated (16.8, 95% confidence interval [CI] 14.0 to 19.5) and the proportion of prescriptions started increased (0.13%, 95% CI 0.08% to 0.18%). INTERPRETATION: The Choosing Wisely Canada recommendation against using a combination of ACE inhibitors and ARBs was not associated with reduced combination therapy use in the targeted conditions. The observed pre-existing declines in this practice questions the process of selecting recommendations, and the optimal implementation and value of Choosing Wisely campaigns without other reinforcing interventions. |
format | Online Article Text |
id | pubmed-9828945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | CMA Impact Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98289452023-01-13 The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis Laba, Tracey-Lea Worthington, Heather C. Cheng, Lucy Chan, Fiona K.I. Bansback, Nick Law, Michael R. CMAJ Open Research BACKGROUND: Choosing Wisely is a high-profile campaign seeking to reduce the use of low-value care. We investigated the impact of a Choosing Wisely Canada recommendation against using a combination of angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for the management of hypertension, heart failure or diabetic nephropathy on population-level use of these medications in British Columbia, Canada. METHODS: We identified all people (any age) who were continuously registered with BC’s Medical Service Plan between 2010 and 2017 with the targeted conditions. Using prescription claims data and an interrupted time-series analysis, we estimated the number of people on combination therapy per month, the proportion of days covered (PDC) by combination therapy per month and proportion of all combination prescriptions started per month in the 2 years before and after the introduction of the recommendation on Oct. 29, 2014. RESULTS: Of 1 104 593 people (mean age 65 yr, standard deviation 16 yr) in our study cohort, 4.6% were exposed to combination therapy, largely prescribed by family physicians (84%). The number of people on combination therapy and the PDC were declining before the recommendation, but the proportion of combination prescriptions started in the 2 years before the recommendation was increasing. After the recommendation, we observed no statistically significant changes in any outcome. The pre-existing downward trend of the monthly number of people decelerated (16.8, 95% confidence interval [CI] 14.0 to 19.5) and the proportion of prescriptions started increased (0.13%, 95% CI 0.08% to 0.18%). INTERPRETATION: The Choosing Wisely Canada recommendation against using a combination of ACE inhibitors and ARBs was not associated with reduced combination therapy use in the targeted conditions. The observed pre-existing declines in this practice questions the process of selecting recommendations, and the optimal implementation and value of Choosing Wisely campaigns without other reinforcing interventions. CMA Impact Inc. 2022-12-13 /pmc/articles/PMC9828945/ /pubmed/36735223 http://dx.doi.org/10.9778/cmajo.20210185 Text en © 2022 CMA Impact Inc. or its licensors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use) and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Research Laba, Tracey-Lea Worthington, Heather C. Cheng, Lucy Chan, Fiona K.I. Bansback, Nick Law, Michael R. The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis |
title | The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis |
title_full | The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis |
title_fullStr | The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis |
title_full_unstemmed | The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis |
title_short | The impact of the Choosing Wisely Canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis |
title_sort | impact of the choosing wisely canada campaign on the simultaneous use of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers: interrupted time-series analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828945/ https://www.ncbi.nlm.nih.gov/pubmed/36735223 http://dx.doi.org/10.9778/cmajo.20210185 |
work_keys_str_mv | AT labatraceylea theimpactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis AT worthingtonheatherc theimpactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis AT chenglucy theimpactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis AT chanfionaki theimpactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis AT bansbacknick theimpactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis AT lawmichaelr theimpactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis AT labatraceylea impactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis AT worthingtonheatherc impactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis AT chenglucy impactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis AT chanfionaki impactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis AT bansbacknick impactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis AT lawmichaelr impactofthechoosingwiselycanadacampaignonthesimultaneoususeofangiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockersinterruptedtimeseriesanalysis |